vs
Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $55.4M, roughly 1.0× PLAYSTUDIOS, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-167.0M).
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
MYPS vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $57.6M |
| Net Profit | $-13.7M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | -17.7% | — |
| Net Margin | -24.7% | — |
| Revenue YoY | -18.3% | 94.1% |
| Net Profit YoY | 38.9% | 71.6% |
| EPS (diluted) | $-0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.4M | $57.6M | ||
| Q3 25 | $57.6M | $49.5M | ||
| Q2 25 | $59.3M | $39.5M | ||
| Q1 25 | $62.7M | $28.5M | ||
| Q4 24 | $67.8M | $29.7M | ||
| Q3 24 | $71.2M | $16.4M | ||
| Q2 24 | $72.6M | $7.3M | ||
| Q1 24 | $77.8M | — |
| Q4 25 | $-13.7M | — | ||
| Q3 25 | $-9.1M | $-30.0M | ||
| Q2 25 | $-2.9M | $-75.8M | ||
| Q1 25 | $-2.9M | $-94.3M | ||
| Q4 24 | $-22.4M | — | ||
| Q3 24 | $-3.1M | $-85.6M | ||
| Q2 24 | $-2.6M | $-91.4M | ||
| Q1 24 | $-567.0K | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | — |
| Q4 25 | -17.7% | — | ||
| Q3 25 | -13.6% | -30.8% | ||
| Q2 25 | -5.9% | -151.7% | ||
| Q1 25 | -4.4% | -276.5% | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -6.7% | -433.0% | ||
| Q2 24 | -5.5% | -1055.4% | ||
| Q1 24 | -2.2% | — |
| Q4 25 | -24.7% | — | ||
| Q3 25 | -15.8% | -60.5% | ||
| Q2 25 | -5.0% | -191.9% | ||
| Q1 25 | -4.6% | -330.7% | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -4.3% | -523.3% | ||
| Q2 24 | -3.6% | -1248.6% | ||
| Q1 24 | -0.7% | — |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.07 | $-0.41 | ||
| Q2 25 | $-0.02 | $-1.05 | ||
| Q1 25 | $-0.02 | $-1.31 | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.02 | $-1.32 | ||
| Q2 24 | $-0.02 | $-1.56 | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.9M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $227.9M | $-438.2M |
| Total Assets | $290.6M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.9M | $130.0M | ||
| Q3 25 | $106.3M | $135.2M | ||
| Q2 25 | $112.9M | $149.6M | ||
| Q1 25 | $107.1M | $212.3M | ||
| Q4 24 | $109.2M | $297.3M | ||
| Q3 24 | $105.2M | $334.7M | ||
| Q2 24 | $106.3M | $276.2M | ||
| Q1 24 | $127.0M | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q1 24 | — | — |
| Q4 25 | $227.9M | $-438.2M | ||
| Q3 25 | $238.9M | $-422.5M | ||
| Q2 25 | $245.3M | $-405.8M | ||
| Q1 25 | $244.1M | $-338.4M | ||
| Q4 24 | $244.7M | $-253.6M | ||
| Q3 24 | $265.2M | $-187.1M | ||
| Q2 24 | $263.6M | $-233.8M | ||
| Q1 24 | $288.4M | — |
| Q4 25 | $290.6M | $259.1M | ||
| Q3 25 | $299.2M | $240.3M | ||
| Q2 25 | $316.2M | $250.2M | ||
| Q1 25 | $313.8M | $294.2M | ||
| Q4 24 | $323.0M | $378.3M | ||
| Q3 24 | $330.6M | $387.0M | ||
| Q2 24 | $333.4M | $319.4M | ||
| Q1 24 | $357.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-166.8M |
| Free Cash FlowOCF − Capex | $3.6M | $-167.0M |
| FCF MarginFCF / Revenue | 6.5% | -290.0% |
| Capex IntensityCapex / Revenue | 0.2% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.4M | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $-166.8M | ||
| Q3 25 | $5.7M | $-14.1M | ||
| Q2 25 | $13.6M | $-62.7M | ||
| Q1 25 | $3.3M | $-84.9M | ||
| Q4 24 | $11.6M | $-266.8M | ||
| Q3 24 | $14.6M | $-63.6M | ||
| Q2 24 | $14.5M | $-70.7M | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $3.6M | $-167.0M | ||
| Q3 25 | $5.4M | $-14.1M | ||
| Q2 25 | $13.2M | $-62.8M | ||
| Q1 25 | $3.2M | $-84.9M | ||
| Q4 24 | $11.5M | $-266.9M | ||
| Q3 24 | $13.9M | $-63.6M | ||
| Q2 24 | $12.8M | $-70.8M | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 6.5% | -290.0% | ||
| Q3 25 | 9.3% | -28.6% | ||
| Q2 25 | 22.3% | -159.0% | ||
| Q1 25 | 5.1% | -297.9% | ||
| Q4 24 | 16.9% | -899.8% | ||
| Q3 24 | 19.6% | -389.0% | ||
| Q2 24 | 17.6% | -966.2% | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 0.2% | 0.4% | ||
| Q3 25 | 0.5% | 0.1% | ||
| Q2 25 | 0.7% | 0.2% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.5% | ||
| Q3 24 | 0.9% | 0.3% | ||
| Q2 24 | 2.4% | 0.6% | ||
| Q1 24 | 1.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
